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Clinically Approved MRI Contrast Agents as Imaging Labels
for a Porous Iron-Based MOF Nanocarrier: A Systematic
Investigation in a Clinical MRI Setting
Konstantin Böll, Andreas Zimpel, Olaf Dietrich, Stefan Wuttke,* and Michael Peller*
Metal-organic framework nanoparticles (MOF NPs) are a promising class of
NP systems that oﬀer versatile and tunable properties. Creating a magnetic
resonance imaging (MRI)-MOF NP platform as a basis for a theranostic drug
delivery system is considered an auspicious approach, as MRI is a routinely
used clinical method allowing real-time imaging. So far clinically approved
MRI contrast agents (CAs) have not been investigated systematically for the
visualization of loading and release from MOF NPs. Here, loading and release
of six clinically approved CAs from the MOF MIL-100(Fe) are investigated in a
clinical MRI setting. Standard procedures, beginning with sample preparation
up to MRI methods, are established for that purpose. Results are reproduced
and veriﬁed by Inductively Coupled Plasma Atomic Emission Spectrometry
(ICP-AES) and thiocyanate testing. The macrocyclic CA gadoterate meglumine
is identiﬁed as the best CA candidate for labeling MIL-100(Fe). The CA is
successfully loaded after 1 h, and also eﬀectively released within the ﬁrst hour.
The MR-active CA and iron residuals in supernatants are diﬀerentiable based
on MRI only and concentrations can be successfully calculated. The presented
systematic approach suggests procedures and MRI-methodology that can be
used as blueprint strategy when labeling porous NPs with clinically approved
MRI CAs.
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1. Introduction
Biomedical imaging labels in combination
with nanocarriers allow for a real-time trac-
ing of that nanocarrier for the assessment
of the biodistribution as well as an under-
standing of the targeting and delivery pro-
cess. One of the most promising aspects of
combining therapy and imaging is to op-
timize the delivery of the drug for a spe-
ciﬁc patient.[1] A long-standing challenge to-
wards this goal is the question whether the
drug has been released and delivered to the
targeted tissue or cells.[2] Themere accumu-
lation of the nanocarrier in the target tis-
sue does not necessarily lead to a higher
bioavailability of the drug.[2,3]
A large library of diﬀerent theranos-
tic nanocarrier systems has been synthe-
sized in order to address this challenge,
but unfortunately these eﬀorts did not re-
sult in a comparable number of clinically
applicable products.[4] As an improvement
of this situation, new promising nanocar-
rier material systems could be tested in
conditions that are as close as possible to their intended later clin-
ical application. This means naturally that imaging labels should
be used which can be visualized with standard clinical imaging
methods.
Magnetic resonance imaging (MRI) is a widespread, very ver-
satile standard clinical imaging method using the nuclear mag-
netic moment of proton spins predominantly of water in the
human body. It is non-invasive, does not require ionizing radi-
ation, and allows for a mapping of the internal structure and
certain aspects of function within the body. Additionally, MRI
oﬀers a variety of approved imaging labels (contrast agents—
CA) and a broad spectrum of signal forming mechanisms, in
principle allowing for a tuned visualization of nanocarriers.[5]
Furthermore, magnetic resonance is a standard analysis method
used in basic, preclinical, and clinical research and therefore can
be expected to simplify translational approach for nanocarrier
development.
The loading and release of anMRI imaging label such as MRI-
CA could allow for the visualization of a successful delivery to the
target site and a release of the CA at the same time.[6] However,
to the best knowledge of the authors, there are no studies com-
paring the loading/release of diﬀerent clinically used MRI-CAs
from porous nanoparticles (NPs) in a systematic way. Addition-
ally, the quantiﬁcation of therapeutic drug concentration, in the
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sense of chemodosimetry, may be envisioned if a correlation of
CA and drug release is possible. The principal feasibility has al-
ready been shown using thermosensitive liposomes loaded with
doxorubicin and MRI CA.[6]
Since porous hybrid NPs provide ideal scaﬀolds for the com-
bination of diﬀerent functional units, they are considered as
promising nanocarrier systems in the ﬁeld of nanomedicine.[1,7]
In this respect, metal-organic framework (MOF) NPs are one
of the most promising nanocarrier systems that oﬀer versa-
tile and tunable properties.[8] Due to their hybrid nature and
high porosity, MOF NPs are considered as ideal host systems
for the controlled delivery of active molecules and/or as a plat-
form for medical imaging. While their limited apertures in-
hibit the loading of large molecules or proteins, MOF NPs
have been shown to be eﬃcient nanocarriers using diﬀer-
ent pharmaceutical agents.[9] In addition, MOFs are biodegrad-
able and they can be constructed from biocompatible building
blocks implying a low toxicology.[8,10] For the study presented
here, MIL-100(Fe) NPs (MIL: Materials of Institute Lavoisier)
were chosen as a model system because they are consid-
ered the most suitable MOF nanocarrier systems for clinical
purposes.[8–11]
To further enhance the clinical applicability of this study, clin-
ically approved, unmodiﬁed MRI CAs were used as imaging
labels for MIL-100(Fe) NPs and the CA loading and release
behavior was systematically investigated in a clinical MRI set-
ting. Diﬀerent CAs with varying chemical and physical prop-
erties are available for clinical MRI and are potentially us-
able as imaging labels.[5,12] Currently, Gd-based CAs are the
de facto standard class of MRI CAs[12] and for that reason,
this study focused on Gd-based CAs only. Although being used
for decades, two classes out of three, linear ionic and linear
nonionic clinically approved Gd-based CA, are currently un-
der discussion for safety issues in speciﬁc patients[13] and only
the third class, consisting of three macrocyclic Gd chelates, is
left in clinical routine.[12] However, as the CA-guest/MOF-host
interactions are strongly inﬂuenced by the individual chem-
ical nature of the CA, the whole spectrum of clinically ap-
proved Gd-based CAs, including those, which are currently un-
der safety discussion, was investigated. A set of six Gd-based
CAs was selected for this study—two macrocyclic Gd chelates
(Dotarem/gadoterate meglumine; Gadovist/gadobutrol), three
linear ionicGd chelates (Magnevist/gadopentetate dimeglumine;
MultiHance/gadobenate dimeglumine; Primovist/gadoxetic acid
disodium) and one linear nonionic Gd chelate (Omnis-
can/gadodiamide; see also Supporting Information).
The research presented here aims to address the question
how loading and release of diﬀerent clinically approved MRI
CAs by porous NPs can be systematically investigated in a
clinical MRI setting. By investigating approved MRI-CAs and
by choosing a clinical MRI system, relevant factors inﬂuenc-
ing the visualization for a potential clinical use were already
an integrative part of this study. One aim of this study was
to ﬁnd applicable MRI methods and test their precision. Fi-
nally, by choosing one of the most studied and promising MOF
drug delivery systems, MIL-100(Fe), the door is being opened
to use these NPs as a future theranostic nanocarrier system as
well as adding a new concept for labeling MOF drug delivery
systems.
2. Results and Discussion
Several clinically approved CA candidates are potentially suitable
for loading into MIL-100(Fe). The ﬁrst step was to identify the
most suitable candidate from several clinically approved MRI-
CAs and to develop a suitable experimental procedure for the se-
lection. The challenge here was that MIL-100(Fe) NPs[11,14] and
naturally the MRI-CAs are both MR-active and it is not straight-
forward to assess loading and release processes in real-time with-
out detailed knowledge of these processes. The separation of the
two contributions is impeded because all these processes can af-
fect the MRI signal in a similar way by changing the relaxation
times T1 and T2 of the water protons (or their reciprocals, i.e., the
relaxation rates R1 and R2). In order to facilitate an unambigu-
ous interpretation of loading and release processes, only super-
natants after removing theNPswere used in the selection process
and also in succeeding experiments.
The MIL-100(Fe) NPs were prepared in a procedure accord-
ing to literature.[11,15] The detailed characterization of those NPs
can be found in Figures S1–S5, Supporting Information. All
results conﬁrm that the NPs are similar to those reported in
literature.[11,15]
2.1. Selecting a Suitable CA for Loading and Development of
Experimental Procedure
Six clinically approved gadolinium-based CAs (Dotarem, Mag-
nevist, Multihance, Primovist, Gadovist, and Omniscan) were
tested applying the same loading procedure for each CA. TheNPs
were incubated for 1 h in 1.25 mm aqueous solution of each CA.
A successful loading of the NPs with the CA was expected to re-
duce the concentration of free CA in the solution and, thus, in
the supernatant after removal of the NPs. NP pellets gained when
preparing the supernatant samples were stored for later analysis
as described below.
In MRI, a decreasing CA concentration will result in decreas-
ing R1 and R2 values. Thus, a successful loading of a CA to
the NPs was expected to result in decreasing relaxation rates in
the supernatant when compared to those relaxation rates before
starting the loading procedure. In case of unsuccessful loading,
no or only minor changes of relaxation rates should be found.
Figure 1 shows R1 values (the corresponding results for R2 are
presented in Figure S6, Supporting Information) of the aque-
ous supernatants of all six CAs used during incubation of MIL-
100(Fe) NPs. For comparison, the ﬁgure shows the relaxation
rates of the respective aqueous solutions containing free CA with
the concentration prepared before the loading procedure. Two
types of results were identiﬁed. In one group, the anticipated re-
laxation rate decrease was detected when using Dotarem, Mag-
nevist, Multihance, and Primovist. This was interpreted as suc-
cessful loading to NPs. Contrary to this decrease of the relaxation
rate, an increase of R1 and R2 was observed in a second group
using Gadovist and Omniscan. Because of this unexpected be-
havior and for veriﬁcation, the whole process was repeated using
three individually prepared sets of samples that were measured
separately. This was also done to test the reproducibility of sam-
ple preparation and MRI methods. Repeating the experiments
showed highly reproducible results (Figures 1 and Figure S6,
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Figure 1. MR measurements of reference solutions (white) and supernatants after incubation of 1 mg MIL-100(Fe) NPs in 1.25 mm aqueous solution
of CA (blue). Three individually prepared sets of samples with each CA were measured. Each error bar shown denotes the standard deviation of the
determined relaxation rate R1 mean values for the three individually prepared and measured samples (corresponding R2 mean values shown in Figure
S6, Supporting Information).
Supporting Information). The ﬁnding of these two groups indi-
cates that other MR-active, competing processes were present in
the second group besides the anticipated eﬀects related to loading
in the ﬁrst group. Such competing processes could potentially be
caused by decomposing Fe-based MOF NPs and concomitantly
increasing iron content in the supernatant, which is itself also
MR-active. Please note that results using Primovist were less re-
producible, compared to the other CAs, although samples were
measured together with those of other CAs. Thus, varying results
were not related to MRImethods and were assumed to be caused
by additional unknown processes of the sample.
Two additional analysis methods were applied for further veri-
ﬁcation of the assumption that the expected relaxation rate reduc-
tion seen in the ﬁrst group is related to a CA-loading process and
to further look into the unexpected results of the second group.
NP pellets that were collected when preparing the supernatants
were analyzed by Inductively Coupled Plasma Atomic Emission
Spectrometry (ICP-AES), determining the ratio of gadolinium to
iron content in each pellet. Additionally, the iron content in the
supernatants was determined using a thiocyanate test with the
idea to identify NP decomposition. The reduced Gd/Fe ratio in
the pellets (Figure 2) indicates a lower uptake of Gadovist and
Omniscan compared to the other four CAs. Additionally, using
Gadovist and Omniscan also leads to an increased iron concen-
tration in the supernatants suggesting a decomposition of the
NPs which could explain the unexpected, increasing relaxation
rates. The other four CAs showed desirable results and were con-
sidered promising for further testing.
The lower CA uptake and the higher release of iron ions into
the solution in group 2 with Gadovist and Omniscan led to their
exclusion for further investigations considering them as unsuit-
able. The results for the loading process with Primovist were less
easily reproducible than the others and thus Primovist was also
excluded. Of the remaining three CAs, Dotarem, Magnevist, and
Multihance, Dotarem was the only macrocyclic CA. Macrocyclic
Gd-based CAs are currently considered to be safer for clinical ap-
plication inside humans.[12] Thus, Dotarem was considered the
most promising candidate for loading into MIL-100(Fe) and the
most suitable CA for a potential later clinical use. Due to the high
experimental eﬀorts, the following investigations focused on us-
ing Dotarem only. The question why the other CAs were less suit-
able or led to unexpected results was considered beyond the scope
of this work.
2.2. Testing CA Loading of Dotarem in Water and Diverse Buﬀers
For further optimization of the loading process and also to test
the sensitivity of the process to varying chemical environments,
diverse buﬀers were tested. Figure 3 and Figure S7, Supporting
Information, show the relaxation rates of the supernatants after
applying the same loading and preparation processes with the
same Dotarem concentration (2 mm) but using water and six dif-
ferent physiological buﬀers. These buﬀers are frequently used in
biology, pharmacy, and biomedicine. Besides bidestilled water,
three representatives of the Good’s-buﬀers (MES, HEPES, and
TRIS) were chosen because of their buﬀer capacity from slightly
acidic (MES) to neutral (HEPES) and slightly basic (TRIS) pH. To
mimic more acidic conditions present, for example, in human
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Figure 2. ICP-AES measurements of removed MIL-100(Fe) NP pellets after incubation in the diﬀerent CAs (gray) and thiocyanate test of the remaining
supernatants (red). The Gd/Fe ratio in the removed NP pellets (gray), determined via ICP-AES, for the CAs Gadovist and Omniscan is lower than for the
other four. The iron concentration in the supernatants (red), determined by a thiocyanate test, reveals a higher iron concentration in the supernatants
for the CAs Gadovist and Omniscan than for the other four CAs.
Figure 3. R1 relaxation rates of supernatant solution after loading of Dotarem to MIL-100(Fe) in water and in 6 diﬀerent buﬀers (blue). The same
loading procedure was used as for sample preparation of Figure 1. Additionally, reference samples containing the speciﬁc solvent with 2 mm Dotarem
were prepared and analyzed (white). The error bars denote the standard deviation of the R1 relaxation rates for each sample. The corresponding R2
relaxation rates are shown in Figure S7, Supporting Information.
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Figure 4. MRI investigation of CA release fromNPs in diverse buﬀers. R1 relaxation rates of supernatant solutions (green) of 1mgMIL-100(Fe) previously
loaded in H2O with a concentration of 2 mm Dotarem. The loaded NPs were exposed for 1 h to six diﬀerent buﬀers before removal and MRI analysis of
the supernatants. For comparison, corresponding buﬀer solutions without CA (white) were also examined. The error bars denote the standard deviation
of the R1 relaxation rates for each sample. The corresponding R2 relaxation rates are displayed in Figure S8, Supporting Information.
cells (late endosomes or lysosomes), HOAc buﬀer was applied.
Additionally, Hank’s balanced salt solution (HBSS) and HBG as
an osmotically balanced equivalent of HEPES (20 mm, contain-
ing 5 mm glucose), were used because of their known physiolog-
ical properties for biomedical applications.
Similar to the preceding experiments using diﬀerent CAs, a
decreased R1 or R2 in the supernatants in comparison to the cor-
responding reference solution was considered indicative for suc-
cessful loading of the CA to the NPs. This was only seen us-
ing water and HEPES. Using the other buﬀers, no loading or
again additional competing MRI signal forming processes were
detected. Due to the known stability of the NPs[11] in water to-
gether with the simpliﬁed use and availability, water was cho-
sen as the medium for all further loading procedures reported
here.
2.3. Testing CA Release of Dotarem in Diverse Buﬀers
Release of Dotarem from NPs loaded in aqueous CA solution
was investigated in six diﬀerent buﬀers (see Figure 4 and Fig-
ure S8, Supporting Information). The diﬀerent solutions were
used to investigate how sensitive the release is to modiﬁed chem-
ical environments and whether one of these is more eﬀective for
testing. The same amount of NPs loaded with CA were redis-
persed and left for 1 h before centrifugation and characterization
of the gained supernatants by MRI. A successful release of CA
was expected to show increased relaxation rates in supernatants
when compared to the corresponding reference solution (without
exposition to loaded NPs). All supernatants of the diverse buﬀers
showed an increase in R1 and R2 which was the ﬁrst indication
that CA is released and will be further analyzed in the following
sections using HBG.
HBG is a commonly used standard buﬀer for in vivo applica-
tions. For this reason,HBGwas chosen for further testing and for
proving principle in the following experiments. The other buﬀers
were not excluded in general and thus could also be used for the
following investigations.
2.4. Precision of MRI Methods and CA Concentration
Assessment
After showing successful Dotarem loading in water and the ﬁrst
experiments investigating release, the precision of theMRImeth-
ods was tested. At ﬁrst,R1 andR2 measurements were carried out
for eight diﬀerent concentrations of Dotarem in water and HBG,
using two separately produced samples per concentration, that
is, 16 samples per solution (see Figures S9 and S10, Supporting
Information). In each case, a linear ﬁt was performed and each
of these resulting ﬁt lines was then used as a calibration curve
to calculate the amount of Dotarem in ﬁve control samples per
solution (see Figures S11, S12, S13, and S14, Supporting Infor-
mation). Additionally, each control sample wasmeasured by ICP-
AES as a control for the MR results.
The MRI results of each sample used for the calibration lines
show a low standard deviation; the error bars in Figures S9
and S10, Supporting Information, are in fact smaller than the
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Figure 5. CA loading of NPs in H2O. Figures show relaxation rates R1 and R2 of supernatants after loading procedures and subsequent centrifugation
of three diﬀerent amounts of loaded NPs. 1 mg (circles), 3 mg (triangles), and 5 mg (pentagons) of MIL-100(Fe) NPs were loaded either in a 2 mm
aqueous Dotarem solution (ﬁlled symbols) or, for reference, in water only (empty symbols). The solid black lines and the dashed lines show the R1 or
R2 of a 2 mm aqueous Dotarem reference solution or of H2O, respectively. Standard deviations for the R1 and R2 results were determined and the only
visible error bar is shown for the R1 result of the 1 mg sample loaded in 2 mm aqueous Dotarem solution. All other error bars are not displayed, as they
were within the boundaries of the markers (i.e., below 0.096 s−1 for R1 results and below 0.057 s
−1 for R2 results)
markers for most of the measurements. The results of the sepa-
rate sample sets (marked as sample set 1 and 2 in Figures S9 and
S10, Supporting Information) are considered equal as demon-
strated by the ﬁgures and showing that the sample production as
well as the MRI measurements are very consistent.
The concentrations of the control samples calculated via MRI
measurements (see Figures S11–S14, Supporting Information)
match the intended concentrations and the concentration deter-
mined by ICP-AES precisely, that is, less than 0.1 mm deviation
from the intended concentration in all but two cases for the cal-
ibration in H2O and one for the calibration in HBG. In those
cases, the deviation was below 0.3 mm.
The slopes of the lines for R1 and R2 shown in Figures S9 and
S10, Supporting Information, are called the relaxivities r1 and r2,
respectively. Relaxivities indicate the contrast changing eﬀective-
ness of a CA in the solution.
Relaxivities for Dotarem in water were reported by several au-
thors in literature. Laurent et al. reported an r1 of 3.1 s
−1mm−1
at 1.41 T,[5] Rohrer et al. state an r1 of 2.7 to 3.1 s
−1mm−1, and
an r2 of 2.5 to 3.9 s
−1mm−1 at 1.5 T and 37 °C[5] and Aime et al.
state an r1 of 3.6 s
−1mm−1 and an r2 of 4.3 s
−1mm−1 at 1.5 T and
37 °C.[16] Considering potential diﬀerences of experimental con-
ditions, that is, temperature, calculation, or imaging methods,
the results shown here (r1 and r2 of 4.0 s
−1mm−1, Figures S9
and S10, Supporting Information) were regarded as valid and in
accordance with literature. These results were also regarded as
veriﬁcation of the MRI and calculation methods applied in this
study.
2.5. Eﬀect of Time and Amounts of NPs on the Loading Process
This section covers the question whether the amount of CA
loaded to MIL-100(Fe) NPs can be further modiﬁed by increas-
ing the loading time periods and by varying the NP amount. The
previously shown loading procedures were all carried out for 1 h.
Figure 5 shows MRI results investigating the loading process
in water with diﬀerent amounts of NPs and diﬀerent incubation
times. A total of 18 loading processes were carried out in 2 mm
aqueous Dotarem solution (1 mL) using three diﬀerent amounts
of NPs (1, 3, and 5mg). For each of these amounts, samples were
exposed to buﬀers for three diﬀerent time periods before NPs
were removed by centrifugation. As a control, samples were pre-
pared performing exactly the same loading process but without
adding CA. The NPs created in these mock loading procedures
will further on be called “empty” NPs. The supernatants acquired
after these loading processes were also analyzed in MRI.
Increasing the NP amount present during loading, resulted in
decreasing relaxation rates (Figure 5), which is consistent with
an increased CA uptake by NPs. Results from supernatants of
loaded and “empty” NPs were clearly separated.
The MRI results for the supernatants of loaded and “empty”
NPs seemed to converge only for the highest NP amount of 5 mg
in R1 or even to overlap in R2 indicating that most of the CA
present during loading is taken up by the NPs.
At the same time, the increasing relaxation rates of super-
natants with increasing amount of “empty” NPs indicate that ei-
ther the NPs cannot fully be removed during centrifugation or
Adv. Therap. 2020, 3, 1900126 1900126 (6 of 12) © 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advtherap.com
Figure 6. Dotarem release from MIL-100(Fe) NPs in HBG. Plots show relaxation rates R1 and R2 of supernatants after release was stopped by removal
of the NPs. In preparations of these experiments, NPs were loaded either in a 2 mm Dotarem aqueous solution (ﬁlled symbols) or, for reference, in
water only (empty symbols) for 1 h. 1 mg (circles), 3 mg (triangles), and 5 mg (pentagons) of these NPs were re-immersed in HBG for investigation of
content release. Standard deviations for the R1 and R2 results were determined but not displayed, as they are all within the boundaries of the markers
(i.e., below 0.051 s−1 for R1 results and below 0.11 s
−1 for R2 results)
that residual NP components are present after partial or even full
disintegration of the NPs. A disintegration of NPs after certain
time periods in water is not a fundamental problem and even
desirable as NPs should be extractable from the body in clinical
use after a certain time. This has to be taken into account when
analyzing MRI results of loading procedures.
Loading processes with CA and time periods of more than 1 h
showed only minor increases of relaxation rates, which indicates
that most of the CA is already taken up within the ﬁrst hour.
This outcome is a favorable result as it allows time savings when
preparing labelled NPs.
2.6. Eﬀect of Time and Amounts of NPs on the Release Process
The release process in HBG was investigated in a similar man-
ner as described for the loading procedure. At ﬁrst MIL-100(Fe)
NPs were incubated in 2 mm aqueous Dotarem solution and ex-
tracted after centrifugation. Release processes with three diﬀer-
ent amounts of NPs (1, 3, and 5 mg) and three diﬀerent incuba-
tion times (1, 5, 24 h) for each of these amounts were then carried
out by incubating the NPs in HBG and removing them after the
speciﬁed incubation time. Mock release processes with the same
parameters were also carried out by using “empty” NPs, that is,
NPs that were previously incubated in water only.
Supernatants, originating from CA loaded NPs, showed a
trend toward increasing relaxation rates between 1 and 5 h
and also increasing relaxation rates with an increase of the
NPs—the higher the amount, the more CA was released into the
solution (see ﬁlled markers in Figure 6). Increasing relaxation
rates in supernatants again implied higher CA content or pre-
ceding CA release from NPs, respectively. After 24 h relaxation
rates seemed stable or starting to decrease again. Most of the CA
release seemed to happen within the ﬁrst hour.
The relaxation rates determined for supernatants from
“empty” NPs (see empty markers in Figure 6) conﬁrmed that the
relaxation rate changes were related to CA release. These results
show almost no dependency onR1 andwere comparable to theR1
of HBG. This was diﬀerent for R2 with increased relaxation rates
of supernatants from “empty” NPs relative to R2 of HBG. These
results did not show a clear trend between diﬀerent amounts of
NPs indicating that some residuals are still present which may
be less compared to those of Figure 5.
The sample marked by the empty pentagon at 24 h in Fig-
ure 6 supposedly contained 5 mg of “empty” NPs but showed
unexpected relaxation rates that would indicate the presence of
DotaremCA. Due to an unintendedmislabeling, this sample was
retrospectively identiﬁed by ICP-AES as being produced not from
“empty” NPs but from CA loaded NPs instead (see next section).
CA is clearly released when loaded NPs were re-immersed in
HBG and increasing amounts of loaded NPs showed increased
CA release as expected. 1 h seemed suﬃcient to release most of
the CA. Increased R2 relaxation rates originating from “empty”
NPs showed that some residuals of NPs besides CA are present
in the supernatants. Results of supernatants from “empty” NPs
did not markedly change although the incubation time during
release and the amounts of NPs were varied. Considering the
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observation that results from loaded NPs were separable from
those of “empty” NPs—especially when larger amounts of NPs
were used—this kind of experiments allows for a detailed in-
vestigation of CA release from NPs. It is recommended to add
similar reference samples in future experiments to assess such
additional signal forming processes besides those originating
from CA loading and release. The presence and assessment of
two MR-active components in a sample is addressed in the next
experiments.
2.7. Assessing and Verifying Concentration of Two MR-Active
Components by MRI
The presence of two diﬀerent MR-active components may be a
major challenge because both aﬀect the MRI signal similarly.
For instance, Gd and Fe will both shorten relaxation times with
increasing concentration. If both are present at the same time
in a solution, a simple determination of R1 and R2 in a macro-
scopic voxel will typically not allow for a diﬀerentiation of the
two individual contributions to signal change. This is a com-
mon problem in MRI because the CA or MR-active components
are not directly visualized by MRI but instead CAs are indirectly
visible by changing the relaxation rates of the signal-giving wa-
ter protons in their near vicinity.[6] This challenge already led to
the use of supernatants in MRI experiments where mainly one
CA, namely Dotarem, was expected in the supernatants. The pre-
ceding results have shown that both, iron-containing contribu-
tions of MIL-100(Fe) NPs and the CA Dotarem, may be present
in the supernatants at same time even after careful removal of
NPs by centrifugation. Thus, it seemed very necessary to ﬁnd an
MRI method allowing the separate identiﬁcation of two diﬀerent
MR-active components without the use of additional non-MRI
methods.
Under certain conditions, when analyzing a solution that con-
tains two known CAs, it is possible to retrieve the concentrations
of both CAs by an MRI method introduced as “dual-contrast –
magnetic resonance ﬁngerprinting” (DC-MRF).[17] A priori infor-
mation for each of the two CAs/MR-active components are re-
quired as a prerequisite for this method to work. The R1 and R2
values for the CA mixture of interest, as well as for the base so-
lution without any CAs, have to be determined. Furthermore, r1
and r2 values for each of the two CAs have to be determined sep-
arately in the base solution of interest. Using this information,
the concentration of both CAs may be calculated as described by
Anderson et al.[17] The feasibility of this method for the charac-
terization of the supernatants was tested here.
The solutions of interest consist of Gd-based CA and Fe-based
NP components acting as a CA. The clinically approved Gd-CA
Dotarem is already well known and relaxivities may be deter-
mined easily by varying the amount of CA in the solution and
performing appropriate MR experiments on those solutions. In
contrast to this, the exact nature of the MR-active components of
MIL-100(Fe) remaining in the supernatant after centrifugation is
unknown. For example, leftover NPs after centrifugation could
aﬀect the MRI results diﬀerently when compared to iron ions or
debris of the NPs. Because of this and the yet not well known dy-
namics, the calibration curves for the “second” CA are hardly as-
sessable beforehand for a speciﬁc supernatant containing a mix-
ture of Fe ions, intact NPs or debris of MIL-100(Fe). Here, as
a surrogate, calibration curves have been determined based on
samples where diﬀerent amounts of NPs were incubated in ei-
ther water or HBG without adding CA. These “empty” NPs were
removed by centrifugation after 1 h with subsequent MRI mea-
surements of the supernatants (see Figures S15 and S16, Sup-
porting Information). Additionally to MRI, the concentration of
iron and gadolinium ions present in the supernatants was also
determined using ICP-AES. Calibration curves for Dotarem have
already been acquired to determine the precision of this method
(see Figures S9 and S10, Supporting Information). Using these
calibration curves and applying the DC-MRF-method, the iron
and gadolinium concentration of the 5- and 24-h samples seen
in Figures 5 and 6 were assessed and compared to the ICP-AES
results.
Figures 7 and 8 show the concentrations of Fe- and Gd-based
on MRI measurements in comparison to the concentrations ob-
tained via ICP-AES for the experiments investigating 5-h CA
loading in water and CA release in HBG, respectively. The corre-
sponding results for the 24 h loading and release experiments are
presented in Figures S17 and S18, Supporting Information. For
the loading experiments (Figure 7 and Figure S17, Supporting In-
formation), the gadolinium concentrations assessed byMRIwere
in good accordance with ICP-AES. On average, the iron content
is overestimated by 0.6 mm with a standard deviation of about
0.2 mm (see Figure 7 and Figure S17, Supporting Information).
This is also true for the CA release process in HBG with the dif-
ference that assessment seems more precise and more accurate
(Figure 8). The iron content was overestimated by about 0.3 mm
with a standard deviation of about 0.3 mm. The gadolinium con-
tent was, on average, underestimated by less than 0.1 mm with a
standard deviation of about 0.1 mm.
The surrogate calibration curves for iron are made from
“empty” NPs which means that potential residual fragments of
loaded NPs are neglected. Furthermore, ICP-AES is “only” count-
ing Fe- and Gd-ions whereas in MRI the signal will be aﬀected
diﬀerently depending on the chemical nature. This means that
two samples containing the same amount of iron but with diﬀer-
ent chemical nature may result in diﬀerent relaxation times. Cal-
ibration curves for clinically approved Gd-based CA do not suﬀer
from such problems as each CA-molecule contains only one Gd-
atom. These could be the reasons for overestimating iron con-
centration using DC-MRF.
Applying the DC-MRF method to supernatants investigating
“CA release” from “empty” NPs, ideally no Gd-content should be
found (empty green markers in Figure 7 and Figure S17, Sup-
porting Information). Instead the method minimally underesti-
mates the gadolinium content and overestimates the iron content
(empty brown/orange markers in Figure 7 and Figure S17, Sup-
porting Information). One explanation for this observation is that
the DC-MRFmethod is highly eﬀective if r1 and r2 of the CAs cali-
bration curves are suﬃciently diﬀerent. In the experiments here,
the calibration curves of Dotarem and the MIL-100(Fe) residu-
als in water were similar. For Dotarem in water, r1 and r2 were
both 4.0 s−1 mm−1 (Figure S9, Supporting Information) and for
the residuals the values for r1 and r2 were very similar, that is, 2.9
and 2.0 s−1 mm−1 (Figure S15, Supporting Information), respec-
tively. In HBG, the r1 and r2 of Dotarem were both 5.0 s
−1 mm−1
(Figure S7, Supporting Information) but very diﬀerent for the
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Figure 7. Bland–Altman plot for the supernatants after the 5-h loading procedures in H2O. The samples used in Figure 5 were analyzed using the
“dual-contrast MRI ﬁngerprinting” method. Blue markers indicate the gadolinium and orange markers indicate the iron content. 1 mg (circles), 3 mg
(triangles), and 5 mg (pentagons) of MIL-100(Fe) NPs were loaded either in a 2 mm aqueous Dotarem solution (ﬁlled symbols) or, for reference, in
water only (empty symbols). ICP-AES was the gold standard.
Figure 8. Bland-Altman plot for the supernatants after the 5-h release procedures in HBG. The samples used in Figure 6 were analyzed using the “dual-
contrast MRI ﬁngerprinting” method. Green markers indicate the gadolinium and orange markers indicate the iron content. NPs were loaded either in
a 2 mm Dotarem aqueous solution (ﬁlled symbols) or, for reference, in water only (empty symbols) for 1 h and were removed afterwards. 1 mg (circles),
3 mg (triangles), and 5 mg (pentagons) of these NPs were re-immersed in HBG for investigation of content release. ICP-AES was the gold standard.
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residuals, that is, 0.1 and 7 s−1 mm−1 (Figure S16, Supporting
Information), respectively. There is also a clear diﬀerence be-
tween the iron content of the samples loaded in 2 mm aqueous
Dotarem solution (ﬁlled markers) and the ones loaded in water
only (empty markers) (Figure 7 and Figure S17, Supporting In-
formation). The supernatants prepared from loaded NPs contain
less iron than those prepared from “empty” NPs. MIL-100(Fe)
NPs with Dotarem attached to them are heavier than the “empty”
NPs and their removal via a centrifuge may be more eﬀective.
This suggests that the MIL-100(Fe) residuals consist mostly of
NPs and not of ions from decomposed NPs. In Figure S13, Sup-
porting Information, this seems evenmore pronounced as based
on ICP-AES results, iron content was very low for the 24 h re-
lease experiments in HBG disregarding whether supernatants of
loaded or “empty” NPs were interpreted. One explanation could
be that NPs in HBG tend to agglomerate at long time periods dis-
regarding the presence of CA and thus NPs or residuals are more
eﬀectively removed from supernatants by centrifugation.
DC-MRFwas successfully used in this study to diﬀerentiate be-
tween the residuals of NPs and CA in the supernatants.While the
CA concentration was accurately determined, Fe concentrations
were overestimated. With further understanding of the nature of
the MIL-100(Fe) residuals, it should be possible to create more
precise calibration curves and further improve the analysis.
3. Conclusion
In this work, six clinically approved and unmodiﬁed MRI CAs
were systematically tested as an imaging label for the porous NPs
MIL-100(Fe). Dotarem was identiﬁed as the best CA for labelling
MIL-100(Fe) NPs enabling MRI visualization of loading and re-
lease. More detailed investigations of the loading and release pro-
cesses, including precision tests of the utilized MRI methods,
were carried out.
Results were thoroughly tested by independently prepared
sample batches and repeated experiments. Additionally, MRI re-
sults were veriﬁed by ICP-AES and thiocyanate-based determina-
tion of gadolinium and iron concentrations. Performed in a clin-
ical MRI system at 1.5 T, the applied MRI methods for R1 and R2
determination were shown to be suitable for the systematic re-
search of CA loading and release processes. Both processes were
shown to happen within the ﬁrst hour and to be strongly depen-
dent on the used buﬀer. Using a clinical MRI setting and clin-
ically approved MRI CAs for labeling porous NPs and in a next
step the nanocarrier system facilitates the translation of results to
clinical application. Based on the results of this study the authors
think that the presentedmethodology can serve as a blueprint for
investigating other promising porous NPs foreseen for MRI vi-
sualization of loading and release processes based on CAs.
MIL-100(Fe) and of course MRI-CAs are both MR-active, af-
fecting the MRI signal by comparable mechanisms. To allow in-
vestigation of CA loading and release processes, supernatants
were analyzed assuming that after centrifugation of NPs only CA
will be the dominating MR-active component. In the course of
this study, it has been shown that besides the expected CA con-
tent also residuals of the iron-based MOF NPs were present af-
ter thorough removal of NPs. This indicates that additional pro-
cesses besides CA loading and release from MIL-100(Fe) have
to be considered in future research. In that case two MR-active
components in a solution are present and to allow diﬀerentiation
the “dual-contrast MRI ﬁngerprinting” method was adapted and
tested successfully. Concentrations of Dotarem and MOF resid-
uals in supernatants were shown to be assessable. The applica-
tion of this method allows a ﬁrst interpretation of MRI results
originating from CA loading or release to MR-active NP nanocar-
rier systems without the need of additional methods such as
ICP-AES.
Labeling of NPs for MRI visualization is typically performed to
trace the NPs and their accumulation in a tissue of interest. The
demonstrated feasibility of NP-loading with clinically approved
CAs adds a new concept of labeling MOF NPs for MRI visual-
ization that has not been investigated in a systematic way before.
Furthermore, successful loading and release of MOF NPs with
an MRI-CA creates a basis for new theranostic MOF NPs as vi-
sualization of release of CA from NPs which may be related to
release of co-loaded drugs and their biodistribution. The feasibil-
ity of such concepts has been shown for liposomes already.[6]
The results found in this study justify further research using
Dotarem (one of the most future-proof CAs) as an imaging label
for the most promising biocompatible MOF NP candidate MIL-
100(Fe) with the aim to develop a drug-delivery system allowing
characterization of loading and release. Co-loading of CAs and
therapeutic drugs to NPs MIL-100(Fe) seems to be the next step
in future research.
4. Experimental Section
MRI Measurements: All MR measurements were performed in a
clinical setting using a Siemens MAGNETOM Aera 1.5T MRI scanner
(Siemens Healthineers, Erlangen, Germany) with a standard head coil.
Samples were ﬁlled into 2 mL Eppendorf-tubes for MRI. An ensemble of
up to 24 samples was ﬁxed in a dedicated PMMA holder and submerged
in a water bath (Figure 9). The bath containing the samples was then
ﬁxed in the head coil. The MRI measurements were performed at room
temperature.
The MRI analysis in this work was based on the determination of re-
laxation times T1 [s] and T2 [s] of supernatant samples under diﬀerent
experimental conditions.
For T1 determination a set of images was acquired using a saturation-
recovery pulse sequence with 30 recovery times between 130 and 5000 ms
and an accordingly adapted TR between 300 and 5150 ms. The other pa-
rameter settings were: TE 1.71ms,matrix 128*128, FOV 126mm*126mm
and slice thickness 6 mm. For each of the 30 recovery times in total 15 ex-
periments were performed. Always ﬁve images for a speciﬁc recovery time
of these 15 were averaged. This resulted in three sets consisting of 30 av-
eraged images with varying saturation times. T1 values were determined
for each set as described below and the mean and standard deviation of
these T1 values are displayed as relaxation rates R1 in Figures 3–6, Figures
S9, S10, S15, and S16, Supporting Information.
For the T2 determination a set of images was created with a multi-echo
sequence that was applied twice with two diﬀerent sets of 16 echo times
that were either in the range 15–240 or 50–800 ms, respectively. Each set
consisted therefore of 16 images. All other parameters were kept constant:
TR 3000 ms, three averages, matrix 256*256, FOV 126 mm*126 mm and
slice thickness 6 mm). The former set of TEs was used for solutions with
a high R2 and the latter for solutions with lower R2.
Both multi-echo sequence sets were repeated three times allowing to
calculate correspondingly three T2 values for each sample as described
below. The mean and standard deviation of the corresponding three
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Figure 9. Simpliﬁed image processing pipeline. In a MRI experiment a set of samples ﬁlled in Eppendorf tubes was simultaneously investigated as
demonstrated by the MRI images on the left (three exemplary images of the 16 samples shown here). For each sample set always two sets of images
were recorded using varying saturation times to determine T1 relaxation times (top row), and varying echo times to determine T2 relaxation times
(bottom row). The two displayed MRI images sets show the same cross section of the Eppendorf tubes containing the samples immersed in a water
bath. A region of interest was selected for each sample to extract the mean signal evolution over saturation or echo time for that speciﬁc sample (here
three samples are marked by colors for demonstration). Finally, a ﬁt (solid lines) of the squares of the extracted signals (marked by crosses), using the
appropriate squared exponential functions, was used to determine the diﬀerent T1 and T2 relaxation times and the corresponding relaxation rates of a
speciﬁc sample.
relaxation rates R2 values are displayed in Figures 5 and 6, S7–10, S15, and
S16, Supporting Information.
Image analysis and calculation of T1 and T2 values was performed us-
ing in-house developed software based on Python (Python Software Foun-
dation. Python Language Reference, available at http://www.python.org).
Regions of interest were selected for each sample to determine the aver-
age of the signal of this sample (a simpliﬁed scheme of this procedure is
shown in Figure 9). The squared signal averages of a sample were plotted
against the corresponding recovery times and echo times for T1 and T2
determination (Figure 9), respectively. For each relaxation time and each
sample a subsequent noise corrected ﬁt was performed on the squares of
the averages using a Levenberg–Marquardt algorithm according to Raya
et al.[18]
The graphs in Figures S9, S10, S15, and S16, Supporting Information,
show the relaxation rates R1 and R2 (Ri = 1/Ti, i= 1,2) of the samples in re-
lation to CA concentration. For clinically approved CAs, Ri values increase
linearly with increasing concentration of CA under the conditions used,[9]
where the slopes represent the relaxivities ri [s
−1 mm−1] (i = 1,2). These
are determined by a linear ﬁt as displayed in Figures S9, S10, S15, and S16,
Supporting Information). The linear ﬁt in this work was performed using
a Levenberg–Marquardt algorithm.
Inductively Coupled Plasma Atomic Emission Spectrometry: In this work,
ICP-AES was used either to assess the composition of NP pellets or the
content of supernatants after a loading or release process. The detailed
preparation of the speciﬁc samples is described in the supporting informa-
tion for each case. Dried NP pellets were digested in 69% (v/v) HNO3 for
trace analysis and subsequently diluted with bi-distilled water to 3% (v/v)
HNO3. The samples were then analyzed for their gadolinium and iron
content by ICP-AES (CCD simultaneous ICP-AES Vista RL, Agilent, Santa
Clara, USA). The wavelengths 335048 and 342246 nm used for gadolin-
ium and the wavelengths 259940 and 239563 nm were used for iron. The
results from these measurements are reported here without standard de-
viation as it was too low to display.
Determination of Iron Content by UV–Vis (Thiocyanate/Rhodanide
Method):
Calibration: The iron content of the supernatant after incubation of
MIL-100(Fe) NPs in diﬀerent CA solutions was determined by UV–vis
spectroscopy, measuring the absorption of the blood-red iron thiocyanate
complex, which is formed by combining thiocyanate and Fe(III) ions in
solutions.
A calibration curve was determined by preparing diﬀerent FeCl3∙6 H2O
solutions with concentrations 0.02, 0.05, 0.1, 0.2, 0.5, and 1 mm (see
Figures S19 and S20, Supporting Information). An access of ammonium
thiocyanate (1 µL, 1 m in H2O) was added to 20 µL of iron ion solu-
tion and after 5 min, UV–vis absorption in the maximum region (480 and
483 nm) was recorded by a NanoDrop 2000 spectrometer (Thermo Fisher
Scientiﬁc, Waltham, USA). Based on this data, the equation of the two
linear calibration curves (480 and 483 nm) was determined and applied
for the calculation of the amount of iron content in the MIL-100(Fe) +
CA supernatant.
Iron Amount of Supernatants: After incubation of the 1 mg MIL-
100(Fe) NPs in the CA solution for 1 h, the MOF NPs were centrifuged
and 20 µL of the supernatant were spiked with 1 µL of ammonium thio-
cyanate solution (1 m). After 5 min, the UV–vis absorption of the solution
was measured at 480 and 483 nm and the iron content was calculated as
the average of both measurements based on the previous calibrations.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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